Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.

Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K.

Sci Transl Med. 2015 Jul 29;7(298):298ra117. doi: 10.1126/scitranslmed.aaa7619.

3.

Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.

Patki M, Salazar Md, Trumbly R, Ratnam M.

Biochem Biophys Res Commun. 2015 Feb 13;457(3):404-11. doi: 10.1016/j.bbrc.2015.01.004. Epub 2015 Jan 9.

4.

Economic evaluation of targeted cancer interventions: critical review and recommendations.

Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA.

Genet Med. 2011 Oct;13(10):853-60. doi: 10.1097/GIM.0b013e31821f3e64. Review.

5.

Consensus recommendations for advancing breast cancer: risk identification and screening in ethnically diverse younger women.

Stojadinovic A, Summers TA, Eberhardt J, Cerussi A, Grundfest W, Peterson CM, Brazaitis M, Krupinski E, Freeman H.

J Cancer. 2011 Apr 20;2:210-27.

6.

Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study.

Stojadinovic A, Eberhardt C, Henry L, Eberhardt J, Elster EA, Peoples GE, Nissan A, Shriver CD.

Eplasty. 2010 Mar 29;10:e25.

7.

Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.

Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C.

Genet Med. 2010 Apr;12(4 Suppl):S15-38. doi: 10.1097/GIM.0b013e3181d5a67b.

8.

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.

Kondo M, Hoshi SL, Toi M.

Br J Cancer. 2009 Jan 27;100(2):281-90. doi: 10.1038/sj.bjc.6604869. Epub 2009 Jan 13.

9.
10.

A new day dawns: women without oestrogen or is a balance best?

Jordan VC.

Breast Cancer Res. 2002;4(6):218-21. Epub 2002 Sep 10.

Items per page

Supplemental Content

Write to the Help Desk